After the directors sold much of their Dendreon stock at the top of the market, Dendreon later announced that its earnings projections were not achieved because of doctors' reluctance to use its treatment when reimbursement for its …
Morris
Many investors appear to be quite bearish on Dendreon Corporation (DNDN), especially if you look at the percentage of the float that is sold short for this stock. Currently, 26.96% of the float is sold short, suggesting an extreme level of …
You brought some new stock picks, beginning with a biotech firm, DNDN the ticker symbol and Dendreon. What do you like about this one? KRAMER: Dendreon to me is a blockbuster. It's revolutionary new way to treat cancer. On May 1 …
Shares of Dendreon surged to their highest point in two years Tuesday after the biotechnology company said its prostate-cancer drug Provenge extended survival, improving its odds of FDA approval. NEW YORK–Shares of Dendreon surged …
However, the analyst retained his Hold rating on the stock, arguing that the stock is in danger of becoming “a perpetual restructuring megacap tech story.” Dendreon Corp. (NASDAQ: DNDN) slumped more than 66% on Thursday, a day …
DNDN is poised to plunge 69.2% -- deeper into penny-stock territory -- after the firm filed for Chapter 11 bankruptcy protection. Dendreon Corporation said it's reached deals with some bond holders regarding a financial restructuring -- …
Shares of Dendreonrose Monday after the company said its breast cancer drug was effective in an early stage clinical trial. The drug ... and a third dose four weeks after the trial began. Dendreon said the drug produced a "significant …
Dendreon Corp.'s share price surged Friday after a Food and Drug Administration advisory panel recommended the agency approve the company's proposed prostate-cancer treatment. The gain reflects optimism about the Seattle …
We don't think a short idea in the name is relevant today, either. We checked around to find out if one could borrow DNDN stock. We are told there is a -9.95% rebate on anything above 200,000 shares. Last quarter, DNDN announced more …
Valeant stock surged as much as 6% Tuesday on the news. Take Dendreon, which makes cancer immunotherapy treatment Provenge, for example. In February 2015, Valeant paid $495 million for Dendreon, which was then in …
Fortune